Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Rocky Baker to Mice

This is a "connection" page, showing publications Rocky Baker has written about Mice.

 
Connection Strength
 
 
 
0.441
 
  1. Haskins K, Delong T, DiLisio JE, Baker RL. Hybrid Insulin Peptides as Antigens and Tolerogens for Pathogenic T Cells in Autoimmune Diabetes. Immunol Rev. 2026 Aug; 341(1):e70142.
    View in: PubMed
    Score: 0.070
  2. Wenzlau JM, Mangold K, Nicholson K, Dang M, Hohenstein AC, Douglas KS, DiLisio JE, Powell R, Delong T, Haskins K, Baker RL. A novel region of the insulin B9-23 sequence is targeted by a HIP-reactive diabetogenic T cell clone. Front Immunol. 2026; 17:1837267.
    View in: PubMed
    Score: 0.070
  3. Baker RL, Jamison BL, Haskins K. Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2019 08; 26(4):195-200.
    View in: PubMed
    Score: 0.043
  4. Baker RL, Bradley B, Wiles TA, Lindsay RS, Barbour G, Delong T, Friedman RS, Haskins K. Cutting Edge: Nonobese Diabetic Mice Deficient in Chromogranin A Are Protected from Autoimmune Diabetes. J Immunol. 2016 Jan 01; 196(1):39-43.
    View in: PubMed
    Score: 0.034
  5. Baker RL, Delong T, Barbour G, Bradley B, Nakayama M, Haskins K. Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice. J Immunol. 2013 Oct 15; 191(8):3990-4.
    View in: PubMed
    Score: 0.029
  6. Baker RL, Mallevaey T, Gapin L, Haskins K. T cells interact with T cells via CD40-CD154 to promote autoimmunity in type 1 diabetes. Eur J Immunol. 2012 Mar; 42(3):672-80.
    View in: PubMed
    Score: 0.026
  7. Baker RL, Wagner DH, Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun. 2008 Dec; 31(4):385-92.
    View in: PubMed
    Score: 0.021
  8. DiLisio JE, Beard KS, Neef T, Miller SD, Wenzlau JM, Nakayama M, D'Antonio MA, Jamison BL, Nicholson KS, Baker RL, Brunetti TM, Gapin L, Haskins K. Antigen-specific immunotherapy with a CD4+ T cell neoepitope restrains CD8+ T cell differentiation in murine pancreatic islet grafts. Nat Commun. 2026 Mar 24; 17(1).
    View in: PubMed
    Score: 0.017
  9. Callebaut A, Guyer P, Baker RL, Gallegos JB, Hohenstein AC, Gottlieb PA, Mathieu C, Overbergh L, Haskins K, James EA. An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes. Diabetes. 2024 05 01; 73(5):743-750.
    View in: PubMed
    Score: 0.015
  10. Crawford SA, Wiles TA, Wenzlau JM, Powell RL, Barbour G, Dang M, Groegler J, Barra JM, Burnette KS, Hohenstein AC, Baker RL, Tse HM, Haskins K, Delong T. Cathepsin D Drives the Formation of Hybrid Insulin Peptides Relevant to the Pathogenesis of Type 1 Diabetes. Diabetes. 2022 12 01; 71(12):2793-2803.
    View in: PubMed
    Score: 0.014
  11. Wenzlau JM, DiLisio JE, Barbour G, Dang M, Hohenstein AC, Nakayama M, Delong T, Baker RL, Haskins K. Insulin B-chain hybrid peptides are agonists for T cells reactive to insulin B:9-23 in autoimmune diabetes. Front Immunol. 2022; 13:926650.
    View in: PubMed
    Score: 0.013
  12. Jamison BL, DiLisio JE, Beard KS, Neef T, Bradley B, Goodman J, Gill RG, Miller SD, Baker RL, Haskins K. Tolerogenic Delivery of a Hybrid Insulin Peptide Markedly Prolongs Islet Graft Survival in the NOD Mouse. Diabetes. 2022 03 01; 71(3):483-496.
    View in: PubMed
    Score: 0.013
  13. Srivastava N, Hu H, Vomund AN, Peterson OJ, Baker RL, Haskins K, Teyton L, Wan X, Unanue ER. Chromogranin A Deficiency Confers Protection From Autoimmune Diabetes via Multiple Mechanisms. Diabetes. 2021 12; 70(12):2860-2870.
    View in: PubMed
    Score: 0.013
  14. Firdessa-Fite R, Johnson SN, Leon MA, Khosravi-Maharlooei M, Baker RL, Sestak JO, Berkland C, Creusot RJ. Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes. Diabetes. 2021 06; 70(6):1334-1346.
    View in: PubMed
    Score: 0.012
  15. Jamison BL, Neef T, Goodspeed A, Bradley B, Baker RL, Miller SD, Haskins K. Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells. J Immunol. 2019 07 01; 203(1):48-57.
    View in: PubMed
    Score: 0.011
  16. Dirice E, Kahraman S, De Jesus DF, El Ouaamari A, Basile G, Baker RL, Yigit B, Piehowski PD, Kim MJ, Dwyer AJ, Ng RWS, Schuster C, Vethe H, Martinov T, Ishikawa Y, Teo AKK, Smith RD, Hu J, Haskins K, Serwold T, Qian WJ, Fife BT, Kissler S, Kulkarni RN. Increased ß-cell proliferation before immune cell invasion prevents progression of type 1 diabetes. Nat Metab. 2019 05; 1(5):509-518.
    View in: PubMed
    Score: 0.011
  17. Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, Reisdorph N, Haskins K. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun. 2017 03; 78:11-18.
    View in: PubMed
    Score: 0.009
  18. Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, Armstrong M, Powell RL, Reisdorph N, Kumar N, Elso CM, DeNicola M, Bottino R, Powers AC, Harlan DM, Kent SC, Mannering SI, Haskins K. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016 Feb 12; 351(6274):711-4.
    View in: PubMed
    Score: 0.009
  19. Delong T, Baker RL, He J, Barbour G, Bradley B, Haskins K. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes. 2012 Dec; 61(12):3239-46.
    View in: PubMed
    Score: 0.007
  20. Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Barbour G, Bradley B, Haskins K. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes. 2011 Sep; 60(9):2325-30.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)